Clinical trials: Low and Intermediate Risk Prostate Cancer
Prostate Cancer
Proton Therapy for Low and Intermediate Risk Prostate Cancer
The purpose of this trial is to give a shorter course (5 ½ weeks) of radiation that has as little side effects on normal bladder and rectal tissues as the usual longer course (8 weeks) of radiation, without decreasing the chance…
- Trial name
- PR04 (NCT00693238)
- Testing
- Low Risk Proton Radiation, Intermediate Risk Proton Radiation
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- University of Florida
Prostate Cancer, Prostate Disease
Focal US-guided Cryo-ablation Using DynaCAD / UroNAV Preplanning / Guidance of Intermediate Risk Prostate Cancer
The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of using…
- Trial name
- NCT04656678
- Testing
- Cryo-ablation Using DynaCAD / UroNAV preplanning / guidance
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwell Health
Prostate Cancer
Hemiablative Focal Brachytherapy Pilot Study
Whole gland LDR brachytherapy has been a well established modality of treating low risk prostate cancer. Treatment in a focal manner has the advantages of reduced toxicity to surrounding organs.
- Trial name
- NCT02643511
- Testing
- Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- St George Hospital, Australia
Prostate Cancer
Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer
This study is being proposed to evaluate the use of moderate hypofractionated proton therapy in low and intermediate risk prostate cancer patients.
- Trial name
- NCT02040610
- Testing
- Hypofractionated Proton Therapy
- Where
- 2 sites in United States
- Volunteers
- 235 people
- Sponsor
- Provision Center for Proton Therapy
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging
Trans-perineal focal laser ablation represents a promising alternative focal therapy option for patients with low-risk or favorable intermediate risk prostate cancer.
- Trial name
- NCT05826470
- Testing
- TRANBERG®|Thermal Therapy System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Genesis Research LLC
Prostate Cancer
Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer
The purpose of this study is to determine whether stereotactic body radiation therapy (SBRT) with simultaneous boost (higher radiation dose) to areas within the prostate with more prominent cancerous growth (intraprostatic…
- Trial name
- Prostate SBRT (NCT01409473)
- Testing
- Prostate SBRT with concurrent boost to intraprostatic lesion(s)
- Where
- 2 sites in United States
- Sponsor
- Rocky Mountain Cancer Centers
Prostate Cancer
Stereotactic Ablative Radiation Therapy for Prostate Cancer
This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of…
- Trial name
- SUPR-SABR (NCT05668351)
- Testing
- SUPR-SABR treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical University of South Carolina
Prostate Cancer
Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)
This study will enroll prostate cancer patients with an unfavorable intermediate- or high-risk diagnosis. The purpose of this study is to determine whether a regimen of pembrolizumab and low dose prostate radiation or low dose…
- Trial name
- TALON (NCT04569461)
- Testing
- pembrolizumab, Low dose prostate radiation, Radical Prostatectomy
- Where
- United States
- Sponsor
- Duke University
Adenocarcinoma of Prostate
Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer
The overall goal of this project is to test an interactive, multi-media decision aid in the form of an electronic clinical decision dashboard designed to improve the quality of clinical decision making for initial treatment of…
- Trial name
- NCT02342626
- Testing
- Dashboard
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Rochester
Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00547339
- Testing
- stereotactic body radiation therapy (SBRT)- 45 Gy, stereotactic body radiation therapy (SBRT) - 47.5 Gy, stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.
- Trial name
- NCT02499848
- Testing
- PRX302
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Sophiris Bio Corp
Prostate Cancer
Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer
On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy/hemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected…
- Trial name
- RETURN (NCT05832736)
- Testing
- Robotic hemi-prostatectomy with urethral preservation
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma of the Prostate
A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer
A single high dose rate brachytherapy (HDR) treatment combined with a short course of external beam radiotherapy (EBRT) is a highly effective and well tolerated treatment for men with intermediate risk prostate cancer.
- Trial name
- NCT01890096
- Testing
- HDR 2 Fraction, HDR 1 Fraction
- Where
- Canada
- Volunteers
- 174 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer
- Trial name
- BRP2 (NCT03424694)
- Testing
- HDR brachytherapy as monotherapy
- Where
- Canada
- Volunteers
- 199 people
- Sponsor
- CR-CSSS Champlain-Charles-Le Moyne
Prostate Adenocarcinoma
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread…
- Trial name
- NCT05050084
- Testing
- Bicalutamide, Buserelin, Darolutamide
- Where
- 576 sites in United States, Canada
- Volunteers
- 2,050 people
- Sponsor
- NRG Oncology
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7
Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer
This randomized phase III trial studies a diet and exercise program based on the Diabetes Prevention Program to promote weight loss and improve health in men with low-risk or low-intermediate-risk prostate cancer on active…
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC V7, Stage IIA Prostate Cancer AJCC v7
- Trial name
- PALS (NCT02454517)
- Testing
- Behavioral Dietary Intervention, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Fred Hutchinson Cancer Center
Localized Prostate Carcinoma
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy.
- Trial name
- BrachyTRACKS (NCT06200974)
- Testing
- High dose rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
The goal of this study is to determine the safety of using PSMA-PET/mpMRI to define radiotherapy targets, while meeting all current planning criteria.
- Trial name
- NCT04243941
- Testing
- 68Ga-HBED-CC-PSMA
- Sponsor
- UNC Lineberger Comprehensive Cancer Center